在阿尔茨海默氏病中,TREM2表达和粉样蛋白-贝塔细胞症
Francesca La Rosa1, Simone Agostini1, Federica Piancone1
1IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
International journal of molecular sciences
|May 27, 2023
概括
阿尔茨海默病患者显示TREM2表达单细胞减少和粉样β清除减少. 然而,可溶性TREM2 (sTREM2) 和TREM2-mRNA水平升高,这表明TREM2在外围阿尔茨海默氏症病理学中的复杂作用.
科学领域:
- 神经免疫学 神经免疫学
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 阿尔茨海默氏病 (AD) 的发病包括外周炎症和粉样β (Aβ) 斑块.
- 在骨髓细胞表达的触发受体2 (TREM2) 对于减轻AD进展的免疫细胞功能至关重要.
- TREM2是一种潜在的边缘诊断和预后生物标志物,用于阿尔茨海默病.
研究的目的:
- 在阿尔茨海默氏病 (AD) 患者中研究可溶性TREM2 (sTREM2) 和TREM2-mRNA水平.
- 在AD中分析TREM2表达单细胞和相关的微RNA (miR-146a-5p,miR-34a-5p).
- 与健康对照组相比,评估AD患者中单细胞的Aβ42细胞化.
主要方法:
- 对血和脑脊液中sTREM2度的分析.
- 在外周血液单核细胞 (PBMC) 中对TREM2-mRNA和TREM2-表达单细胞的量化.
- 使用AMNIS FlowSight测量miR-146a-5p和miR-34a-5p的表达和Aβ42细胞化.
主要成果:
- 与健康对照组 (HC) 相比,AD患者的TREM2表达单细胞减少.
- 在AD患者中,血sTREM2度和TREM2-mRNA显著上调.
- 在阿尔茨海默病患者中,Aβ42细胞减少,miR-34a-5p和miR-146a-5p的表达发生变化.
结论:
- 周围TREM2表达和功能在阿尔茨海默氏症中发生变化.
- 升高的sTREM2和TREM2-mRNA表明在AD病变发生过程中发挥了复杂的作用.
- 作为潜在的阿尔茨海默病生物标志物,TREM2和相关的微RNA需要进一步研究.
相关概念视频
01:00Enzyme-linked Receptors
78.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.9K
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:26Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226